| P2RY14 Gene |
|---|
| Gene Symbol | P2RY14 |
| Full Name | Purinergic Receptor P2Y14 |
| Chromosomal Location | 3q25.1 |
| NCBI Gene ID | 9939 |
| UniProt ID | Q9HC97 |
| Aliases | GPR105, P2Y14, GPR158 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), Stroke, Inflammatory diseases |
P2RY14 (Purinergic Receptor P2Y14) encodes a G-protein coupled receptor that responds to UDP-sugars (particularly UDP-glucose, UDP-galactose, and UDP-N-acetylglucosamine) and mediates immune and inflammatory responses. It is uniquely activated by extracellular nucleotides attached to sugar moieties, distinguishing it from other P2Y receptors that respond to nucleotides alone. P2RY14 is increasingly recognized as an important player in neuroinflammation and neurodegenerative diseases.
¶ Gene Structure and Evolution
P2RY14 is located on chromosome 3q25.1 and encodes a 336-amino acid GPCR belonging to the P2Y receptor family. The gene has evolved from an ancestral P2Y receptor through gene duplication and divergence, acquiring the unique ability to respond to UDP-sugars rather than simple nucleotides. This specialization likely evolved to respond to damage-associated molecular patterns (DAMPs) released during cellular stress and tissue injury.
¶ Protein Structure and Pharmacology
P2RY14 is a Class A GPCR with seven transmembrane domains:
- N-terminus: Extracellular, glycosylation sites
- Transmembrane domains: 7 α-helices crossing the membrane
- C-terminus: Intracellular, involved in G protein coupling and desensitization
- Disulfide bond: Conserved between extracellular loops
¶ Ligand Recognition
P2RY14 has unique pharmacological properties:
Endogenous Agonists (in order of potency):
- UDP-glucose (most potent)
- UDP-galactose
- UDP-GlcNAc
- UDP-xylose
- UDP (weak activity)
Selectivity:
- Unlike other P2Y receptors, P2RY14 does not respond to ATP, ADP, UTP, or UDP alone
- Requires the sugar moiety for activation
- This distinguishes it from P2RY2 (UTP/ATP responsive) and P2Y12 (ADP responsive)
graph TD
A["UDP-sugars"] --> B["P2RY14"]
B --> C["Gi/o protein"]
C --> D["↓ cAMP"]
C --> E["βγ subunits"]
D --> F["PKA inhibition"]
E --> G["PI3K/Akt pathway"]
E --> H["MAPK pathway"]
F --> I["Modulate<br/>inflammation"]
G --> J["Cell survival"]
H --> K["Gene expression"]
B --> L["β-arrestin"]
L --> M["Receptor<br/>desensitization"]
L --> N["Internalization"]
P2RY14 is highly expressed in immune tissues and regulates:
Mast Cell Function
- Inhibits IgE-mediated degranulation
- Modulates allergic responses
- Regulates histamine release
Neutrophil Chemotaxis
- Guides neutrophil migration to sites of inflammation
- Responds to damage-associated UDP-sugars
- Regulates inflammatory cell recruitment
Cytokine Production
- Modulates pro-inflammatory cytokine release
- Regulates NLRP3 inflammasome activity
- Controls chemokine production
P2RY14 plays a role in:
- Hematopoietic stem cell mobilization
- Mesenchymal stem cell function
- Stem cell niche regulation
- High expression in enteric nervous system
- Modulates intestinal motility
- Involved in gut mucosal defense
P2RY14 is implicated in AD through multiple mechanisms:
Neuroinflammation
- P2RY14 is upregulated in AD brain
- Activated microglia express P2RY14
- UDP-sugar release from damaged cells activates P2RY14
- Creates feed-forward inflammatory loop
Amyloid Response
- Aβ peptides can induce UDP-sugar release from neurons and glia
- P2RY14 activation amplifies microglial inflammatory response
- May contribute to chronic neuroinflammation
Glial Activation
- P2RY14 modulates microglial phenotype
- Affects astrocyte reactivity
- Contributes to neurotoxic glial states
Therapeutic Potential
- P2RY14 antagonists may reduce neuroinflammation
- Preclinical studies show promise
- Brain-penetrant antagonists under development
In PD, P2RY14 is involved in:
Dopaminergic Neuron Degeneration
- P2RY14 expression increases in PD substantia nigra
- Contributes to inflammatory loss of dopaminergic neurons
- Microglial P2RY14 activation promotes neurotoxicity
Neuroinflammation
- P2RY14 contributes to microglial activation
- Responds to α-synuclein-triggered UDP-sugar release
- Amplifies NLRP3 inflammasome activation
Gut-Brain Axis
- P2RY14 in enteric nervous system may relate to PD gut symptoms
- α-Synuclein spread hypothesis involves gut neurons
- UDP-sugar signaling may participate in this pathway
P2RY14 contributes to MS pathology:
EAE Models
- P2RY14 knockout mice show reduced EAE severity
- P2RY14 antagonists reduce demyelination
- Contributes to oligodendrocyte injury
Inflammatory Responses
- P2RY14 on microglia and astrocytes
- Drives pro-inflammatory cytokine production
- Promotes immune cell infiltration
¶ Stroke and Brain Injury
In acute brain injury:
Damage-Associated Molecular Patterns
- Brain injury releases UDP-sugars
- P2RY14 activation contributes to secondary damage
- P2RY14 antagonists show neuroprotection in stroke models
Inflammatory Damage
- P2RY14 on activated microglia
- Contributes to blood-brain barrier breakdown
- Exacerbates neuronal injury
P2RY14 is expressed in:
- Immune tissues: Spleen, thymus, bone marrow (highest)
- Brain: Cortex, hippocampus, cerebellum
- Gut: Enteric nervous system, intestinal epithelium
- Lung: Epithelial cells
- Platelets: Low expression
In the brain, P2RY14 is expressed in:
P2RY14 expression is regulated by:
- Inflammatory cytokines (IL-1β, TNF-α)
- LPS and pathogen-associated patterns
- Cellular stress and damage
- Glucocorticoids (suppression)
graph TD
A["Cell Damage"] --> B["UDP-sugars<br/>Release"]
B --> C["P2RY14"]
C --> D["Gi/o signaling"]
D --> E["NLRP3<br/>Inflammasome"]
E --> F["IL-1β<br/>Processing"]
F --> G["Pro-inflammatory<br/>Cytokine Release"]
G --> H["Neuroinflammation"]
G --> I["Immune Cell<br/>Recruitment"]
| Interactor |
Interaction Type |
Functional Effect |
| UDP-glucose |
Endogenous agonist |
Receptor activation |
| β-arrestin |
Arrestin recruitment |
Desensitization, internalization |
| NLRP3 |
Inflammasome |
Inflammatory signaling |
| Gi/o proteins |
G protein coupling |
cAMP inhibition, βγ signaling |
| GRK |
Kinase |
Receptor phosphorylation |
Antagonists (selectivity for P2RY14):
- MRS2578: First selective antagonist (limited brain penetration)
- PPTN: Highly selective antagonist with in vivo efficacy
- ARB-242901: Brain-penetrant antagonist, preclinical
- Various scaffolds: In development
Agonists:
- UDP-glucose: Endogenous agonist
- MRS2905: Selective agonist (research use)
- No P2RY14-targeted drugs approved yet
- P2RY14 antagonists in clinical trials for inflammatory diseases
- Preclinical data support neuroinflammatory applications
- Biomarker development underway
- Brain-penetrant antagonists needed for CNS applications
- Selectivity over other P2Y receptors critical
- Understanding context-dependent functions
- Potential for immune system side effects
- P2RY14 antagonists in neurodegenerative disease models
- Understanding P2RY14-microglia interactions
- Developing brain-penetrant compounds
- Biomarker development
- Clinical trials for neuroinflammation
- Gene therapy approaches
- Combination therapies
- Personalized medicine approaches